Patent landscape of platelet growth factor receptor and c-KIT targets

Zhang, Hai-Long1; Kong, Qian2

2023-09-01

10.4155/ppa-2023-0005

PHARMACEUTICAL PATENT ANALYST   Impact Factor & Quartile

2046-8954

2046-8962

Type III receptor tyrosine kinase, e.g., PDGFR, are associated with various autoimmune diseases. To show the status of PDGFR and c-KIT targets, we performed the US patent analysis. The present study showed that the R & D of c-KIT target was much earlier than the R & D of PDGFR targets. Currently, the PDGFR-based target demonstrates more applications in the development of biological therapy. Our findings indicated that some inhibitors of c-KIT target contained sulfur elements or 1,3-diazine rings. The c-KIT target has more competitive edges for chemical drug discovery than the PDGFR target. c-KIT and PDGFR targets are currently preferable for drug discovery in autoimmune diseases. This study was the first to show R & D differentiation between PDGFR and c-KIT targets in drug development.

c-KIT patent patent landscape PDGFR targeted drug

ESCI

English

Others

Pharmacology & Pharmacy

Pharmacology & Pharmacy

WOS:001072870900001

Newlands Press Ltd

Web of Science

1.Cent Int Intellectual Property Baotou Co Ltd, Baotou 014030, Peoples R China
2.Southern Univ Sci & Technol, Coll Sci, Dept Chem, Shenzhen 518055, Peoples R China

Zhang, Hai-Long,Kong, Qian. Patent landscape of platelet growth factor receptor and c-KIT targets[J]. PHARMACEUTICAL PATENT ANALYST,2023.

Zhang, Hai-Long,&Kong, Qian.(2023).Patent landscape of platelet growth factor receptor and c-KIT targets.PHARMACEUTICAL PATENT ANALYST.

Zhang, Hai-Long,et al."Patent landscape of platelet growth factor receptor and c-KIT targets".PHARMACEUTICAL PATENT ANALYST (2023).